Document is current
Any future updates will be listed below
-
Authors
Wangler, Sabrina https://orcid.org/0009-0006-3618-0797
Jarczok, Marc N.
Ennis, Matthew
Herhaus, Benedict
Wagner, Róbert
Sehgal, Ratika
Heni, Martin https://orcid.org/0000-0002-8462-3832
- License Information
-
More Information
Article History
Accepted: 27 November 2025
First Online: 5 January 2026
Competing interests
: M.N.J. reports scientific consultation work for LaVita GmbH. R.W. reports receiving lecture fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi-Aventis, and has served on the advisory board for Akcea Therapeutics, Daiichi Sankyo, Eli Lilly, Novo Nordisk and Sanofi-Aventis. M.H. reports receiving lecture fees from Amryt/Chiesi, AstraZeneca, Bayer, Boehringer Ingelheim, Daichii Sankyo, Lilly, Novartis, Novo Nordisk and Sanofi-Aventis. He has also served on advisory boards for Amryt/Chiesi and Boehringer Ingelheim. He is currently a board member of the German Diabetes Association. The other authors declare no competing interests.
